Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics appointed Elizabeth Laws, Ph.D., as Senior Vice President and Global Program Team Leader for KT-621, leveraging her experience leading the Dupixent franchise at Sanofi. The company confirmed KT-621 Phase 2b trials are active in atopic dermatitis and asthma, with data expected by year-end 2026 and late 2027 respectively.
Key figures
- Drug Name
- KT-621
- Phase Of Trial
- Phase 2b
- Phase 3 ad planned start
- mid-2027
- Phase 2b ad data expected
- year-end 2026
- Phase 2b asthma data expected
- late 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.